The FDA tends to approve cancer drugs faster than other agencies, but there is no link between faster review and high clinical benefit.
Tisagenlecleucel can produce responses in children and young adults with relapsed/refractory B-cell non-Hodgkin lymphoma, a phase 2 study suggests.
White women were more likely than Asian, Black, and Hispanic women to have a biopsy within 30 days or 60 days of an abnormal result.
The G8 and CARG chemotherapy toxicity assessment tools were found to predict early hospitalization/ER visits and death in older patients with cancer.
Among patients with AIDS-related lymphoma, hypoalbuminemia is linked to worse overall survival and progression-free survival.
Researchers found that women made up 41% of cancer trial participants but 51% of the cancer patient population.
Although adverse events were more likely with mRNA-based COVID-19 vaccines, the benefits of mRNA vaccination exceeded the risks.
At 10 years, the disease-free survival rate was 54.5%, and the overall survival rate was 50.7%.
Induction chemotherapy was associated with improvements in disease-free, failure-free, relapse-free, and progression-free survival.
Obinutuzumab plus chemotherapy improved progression-free survival and time to next treatment.